RecruitingNot Applicable

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

United States20 participantsStarted 2022-06-10

Plain-language summary

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: \- THOR LX2.3 with LED Lollipop

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis. * Age ≥18 years. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT. * Participants who have a history of radiation therapy to the head and neck. * Participants who have a history of photosensitivity or underlying disease with known photosensitivity. * Participants who are planned to receive palifermin for OM prevention.

What they're measuring

Duration of severe Oral Mucositis

Timeframe: 20 Days

Trial details

NCT IDNCT05335434

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-20

Contact for this trial

Kentaro Ikeda, DDS,MPH

617-732-6570 kikeda4@bwh.harvard.edu

View on ClinicalTrials.gov More Myeloablative Allogeneic Hematopoietic Cell Transplantation trials